Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

exemestane

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Aromatase inhibitor

Related drugs:

‹

anastrozole (23)

anastrozole (23)

›

ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	exemestane Sensitive: A1 - Approval exemestane Sensitive : A1	exemestane Sensitive: A1 - Approval exemestane Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	exemestane Sensitive: A1 - Approval exemestane Sensitive : A1	exemestane Sensitive: A1 - Approval exemestane Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2
ER mutation	Hormone Receptor Positive Breast Cancer	ER mutation	Hormone Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials exemestane Resistant : B	exemestane Resistant: B - Late Trials exemestane Resistant : B
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials exemestane Resistant : B	exemestane Resistant: B - Late Trials exemestane Resistant : B
ER rs2234693	Hormone Receptor Positive Breast Cancer	ER rs2234693	Hormone Receptor Positive Breast Cancer	exemestane Sensitive: B - Late Trials exemestane Sensitive : B	exemestane Sensitive: B - Late Trials exemestane Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	exemestane Sensitive: C1 - Off-label exemestane Sensitive : C1	exemestane Sensitive: C1 - Off-label exemestane Sensitive : C1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	HDAC inhibitor + exemestane Sensitive: C2 – Inclusion Criteria HDAC inhibitor + exemestane Sensitive : C2	HDAC inhibitor + exemestane Sensitive: C2 – Inclusion Criteria HDAC inhibitor + exemestane Sensitive : C2
ER positive + PGR positive	HER2 Negative Breast Cancer	ER positive + PGR positive	HER2 Negative Breast Cancer	exemestane Sensitive: C3 – Early Trials exemestane Sensitive : C3	exemestane Sensitive: C3 – Early Trials exemestane Sensitive : C3
PIK3CA mutation	Hormone Receptor Positive Breast Cancer	PIK3CA mutation	Hormone Receptor Positive Breast Cancer	everolimus + exemestane Sensitive: C3 – Early Trials everolimus + exemestane Sensitive : C3	everolimus + exemestane Sensitive: C3 – Early Trials everolimus + exemestane Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	exemestane + mTOR inhibitor Sensitive: C3 – Early Trials exemestane + mTOR inhibitor Sensitive : C3	exemestane + mTOR inhibitor Sensitive: C3 – Early Trials exemestane + mTOR inhibitor Sensitive : C3